Related Experiment Video
Updated: May 22, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Radiotherapy on hidradenocarcinoma
Issam Lalya1, Khalid Hadadi, El Mehdi Tazi
1Department of Radiotherapy, Military Hospital Mohamed V, Rabat, Morocco.
North American Journal of Medical Sciences
|April 28, 2012
Summary
Postoperative radiotherapy is crucial for managing aggressive clear cell hidradenocarcinoma, especially when recurrence indicators are present. This treatment offers better local control for this rare sweat gland carcinoma.
Area of Science:
- Oncology
- Dermatopathology
Background:
- Clear cell hidradenocarcinoma is a rare, aggressive sweat gland carcinoma.
- Metastasis commonly occurs in regional lymph nodes and distant viscera.
- Surgical resection with clear margins is the primary treatment modality.
Observation:
- A case of a 68-year-old woman with invasive clear cell hidradenocarcinoma in the left parotid area is presented.
- The tumor recurred 5 months post-surgery.
- High-dose irradiation (66 Gy to tumor bed, 50 Gy to lymphatic chains) successfully managed the recurrence.
Findings:
- The patient achieved good local control with minimal toxicity after over 15 months of follow-up.
- Postoperative radiotherapy demonstrated efficacy in managing recurrent clear cell hidradenocarcinoma.
- Specific histological features predict recurrence risk.
Implications:
- Postoperative radiotherapy should be considered mandatory for clear cell hidradenocarcinoma with adverse prognostic factors.
- Adverse prognostic factors include positive margins, poor differentiation, perineural/vascular/lymphatic invasion, lymph node involvement, and extracapsular spread.
- Radiotherapy improves local control and outcomes in high-risk cases.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...